You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Genes and pathways related to mesenchymal biology, connective tissue, and conditions like obesity came to the forefront when researchers analyzed the new susceptibility loci.
Genome-wide association study hits can uncover potential therapies for conditions like inflammatory bowel disease, a Biology of Genomes speaker said.
Diversigen will act as a central lab for generating and incorporating microbiome data into the Crohn's & Colitis Foundation's IBD Plexus platform.
The company said it will use the proceeds to accelerate development of its gastrointestinal platform, including diagnostics and therapeutics for the GI tract.
The firm said that a number of hospitals and labs are expected to evaluate the panel, presenting it with about a $2.0 million annual revenue opportunity.
The Dutch firm expects its product to be the first commercial test on the market to diagnose IBD by analyzing a patient's gut microbiome.
The firm's treatments are based on stimulating the innate immune system with drugs made from inactivated bacteria to restore normal immune function.
The model incorporates clinical, serological, and gene expression factors, and could be used to tailor treatment choices.
The firm's GI panel has also been recently evaluated in pediatric populations, demonstrating a marked increase in overall pathogen detection.
Nearly 8,000 patients participated in a screening study that used a PCR-based detection assay from Becton Dickinson, uncovering a 5 percent carrier rate.
On an organic basis, Q1 revenues grew more than 11 percent, driven in part by strong sales of its FilmArray, Vidas, and Vitek product portfolios.
The high-throughput system is now approved with the firm's Blood Culture ID, Gastrointestinal, Meningitis/Encephalitis, and the previously approved Respiratory Panel.
NPR reports the US Food and Drug Administration has approved a treatment for a genetic disorder that causes rapid aging.
Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.
ScienceInsider reports Nature Communications is reviewing a paper on mentorship following social media criticism arguing it is sexist.
In PLOS this week: method to account for sequencing errors in phylogenies, study of influenza A in Switzerland, and more.